Novel drugs from Anavex hope to reverse Alzheimer's damage amid a stagnant marketplace

Alzheimer’s is not an easy disease to research and develop around. The physical and psychological manifestations of the illness, combined with the difficulties in knowing whether treatment is indeed effective, which in turn mean long periods of time needed for study, results in a hugely underserved therapy area with little immediate incentive for businesses to innovate. The lack of biomarkers makes clinical trials difficult to quantify, and the best biomarker in Alzheimer’s is memory improvement, requiring very sensitive measurements.

Beyond cholinterase inhibitors and memantine